Invex Therapeutics Ltd

IXC

Company Profile

  • Business description

    Invex Therapeutics Ltd is a biopharmaceutical company focused on repurposing the approved drug Exenatide for the treatment of neurological conditions derived from or involving raised intracranial pressure, including Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. The Group's activities include the research and development of Exenatide, including pre-clinical research in Alzheimer's disease in collaboration with Tessara Therapeutics. It operates in one segment, comprising research and development activities within Australia.

  • Contact

    101 St Georges Terrace
    Level 3
    PerthWA6000
    AUS

    T: +61 865580886

    https://www.invextherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    Employees

Stocks News & Analysis

stocks

Reassuring organic growth for undervalued ASX share

Efficiency gains are starting to make their mark.
stocks

Big IPOs are enticing but are they good investments?

Historically, buzzy debuts have been painful for buyers.
stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,692.80143.80-1.63%
CAC 407,979.53101.21-1.25%
DAX 4025,025.98437.83-1.72%
Dow JONES (US)49,097.061,101.11-2.19%
FTSE 10010,380.1372.55-0.69%
HKSE22,410.80430.82-1.89%
NASDAQ23,879.20550.69-2.25%
Nikkei 22556,436.653,007.56-5.06%
NZX 50 Index14,107.41139.84-0.98%
S&P 5007,175.83147.80-2.02%
S&P/ASX 2008,592.60137.80-1.58%
SSE Composite Index3,533.7943.82-1.22%

Market Movers